Published on 23 Apr 2024 on Zacks via Yahoo Finance
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Corcept Therapeutics Incorporated CORT announced positive data from one part of the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with all etiologies of endogenous Cushing’s syndrome.
The GRACE study consists of two parts. The above mentioned data was from the open-label portion of the study in which patients with Cushing’s syndrome and either hypertension, hyperglycemia or both were treated with relacorilant for a period of 22 weeks.